Home/Filings/4/0001171843-14-000307
4//SEC Filing

Sucampo Pharmaceuticals, Inc. 4

Accession 0001171843-14-000307

CIK 0001365216operating

Filed

Jan 22, 7:00 PM ET

Accepted

Jan 23, 7:33 AM ET

Size

7.9 KB

Accession

0001171843-14-000307

Insider Transaction Report

Form 4
Period: 2014-01-13
Dolecek Gayle R
DirectorVP of Research & Development
Transactions
  • Exercise/Conversion

    Common Stock

    2014-01-13$4.41/sh+9,066$39,9819,066 total
  • Sale

    Common Stock

    2014-01-13$9.21/sh9,066$83,4980 total
  • Exercise/Conversion

    Employee Stock Option (Right to Buy)

    2014-01-139,066323,634 total
    Exercise: $4.41Exp: 2021-05-02Common Stock (9,066 underlying)
Footnotes (2)
  • [F1]The sales reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the reporting person on June 13, 2013
  • [F2]5,000 exercisable 5/2/2012; 4,066 exercisable 5/2/2013

Issuer

Sucampo Pharmaceuticals, Inc.

CIK 0001365216

Entity typeoperating

Related Parties

1
  • filerCIK 0001365216

Filing Metadata

Form type
4
Filed
Jan 22, 7:00 PM ET
Accepted
Jan 23, 7:33 AM ET
Size
7.9 KB